替格瑞洛对急性冠脉综合征患者急诊行介入治疗的疗效观察

目的：探讨替格瑞洛对急性冠脉综合征（ ACS）患者急诊介入治疗给予负荷剂量后的起效时间及近期安全性的影响。方法选择100例在发病12小时内急诊行介入治疗的ACS患者，随机分成替格瑞洛组和氯吡格雷组各50例，两组患者入院诊断明确后分别立即给予替格瑞洛180 mg和氯吡格雷600 mg，术后两组分别给予替格瑞洛90 mg／d二次和氯吡格雷75 mg／d的维持治疗，观察给药前及给药后0．5、2、24 h及7天时的血小板聚集抑制率，以及30天内的主要心血管事件及出血发生率。结果①相同时间点的两组比较，替格瑞洛组的血小板聚集抑制率高，差异有统计学意义（ P＜0．01）；②两组30天内的主要心血管事件的发生率比较差异有统计学意义（ P＜0．05）；③两组出血发生率比较差异无统计学意义（ P＞0．05）。结论替格瑞洛较氯吡格雷起效更快，抑制血小板聚集作用更强，有效减少心血管事件发生，同时不增加出血风险。

Ticagrelor of Emergency Interventional Therapy in Patients with Acute Coronary Syndrome Curative Effect Observation

Objective Ticagrelor of emergency interventional therapy in patients with acute coronary syndrome ( ACS) for loading dose after work time and the impact of the recent safety.Methods Choose 100 cases in within 12 hours of emergency interventional treatment of ACS patients, randomly divided into group for Ticagrelor and clopidogrel group of 50 cases, two groups of patients admitted to hospital after diagnosis clear an immediate for Ticagrelor 180 mg and clopidogrel 600 mg, postoperative two groups were given for Ticagrelor secondary 90 mg/day and 75 mg/day of clopi-dogrel maintenance treatment, observation before dosing and 0.5 hours after the treatment, 2 hours, 24 hours and 7 days of platelet aggregation inhibition rate, and the incidence of major cardiovascular events and bleeding within 30 days.Re-sults ①comparing the two groups of the same point in time, on behalf of Ticagrelor set of platelet aggregation inhibition rate is high, the difference was statistically significant ( P<0.01); ②two groups of 30 days of the incidence of major cardiovascular events compared difference was statistically significant ( P<0.05 ); ③ the difference of incidence of bleeding compared the two groups has no statistical significance ( P>0.05 ) .Conclusions For Ticagrelor compared with clopidogrel work faster, stronger inhibiting platelet aggregation and reduce cardiovascular events, at the same time does not increase the risk of bleeding.